| Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas |
NCT02175784: A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus |
|
|
| Completed | 4 | 262 | Japan | ipragliflozin, ASP1941, Suglat, placebo | Astellas Pharma Inc | Type 2 Diabetes Mellitus | 03/15 | 12/15 | | |
NCT02291874: Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM) |
|
|
| Completed | 4 | 100 | Japan | Ipragliflozin, Suglat tablet, ASP1941 | Astellas Pharma Inc | Type 2 Diabetes Mellitus | 07/16 | 07/16 | | |
NCT02791035: Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin |
|
|
| Completed | 4 | 100 | RoW | Oral administration of Ipragliflozin | Asan Medical Center, Severance Hospital, Samsung Medical Center, Kyung Hee University Hospital at Gangdong, Astellas Pharma Korea, Inc. | Type 2 Diabetes Mellitus | 03/17 | 03/17 | | |
NCT02875821: Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone |
|
|
| Completed | 4 | 44 | RoW | Ipragliflozin, Suglat®, metformin with pioglitazone | Yonsei University | Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD) | 06/17 | 06/17 | | |
NCT02847091: Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy |
|
|
| Completed | 4 | 103 | Japan | Ipragliflozin, ASP1941, Suglat, Insulin | Astellas Pharma Inc | Type 2 Diabetes Mellitus | 11/17 | 11/17 | | |
